Hikma PHarmaceuticals Plc annual rePort 2013 NOTES TO THE CONSOLIDATED FINANCIALSTATEMENTS Continued 30.
Derivative financial instruments continueD interest rate swaps the group uses interest rate swaps to manage its exposure to interest rate movements on its bank borrowings.
these contracts have nominal values of $128 million 2012: $158 million and have fixed interest payments at rates ranging from 1.41% to 4.34% 2012: 1.41% to 4.34% forperiods up until 2018 and have floating interest receipts at liBor or euriBor.
the fair value of swaps entered into by the group is estimated as a liability of $1 million 2012: liability of $4 million.
these amounts are based on fair values provided by the banks that originated the swaps and are based on equivalent instruments at the balance sheet date.
some oftheseinterest rate swaps are designated as effective cash flow hedges and the movement in fair value, totalling a gain of $3 million 2012: loss of $2 million has been reflected in other comprehensive income.
the remaining outstanding interest rate swaps that the group wascommitted to atthe year end are held at fair value through profit and loss.
the group believes that the effect on the value of interest rate swaps by interest rate fluctuations will not materially affect the financial position of the group.
31. sHare caPital 2013 2012 issued and fully paid included in shareholders equity: number m $m number m $m At 1 January 197 35 196 35 issued during the year 1 1 At 31 December 198 35 197 35 32. non-controlling interests 2013 2012 $m $m At 1 January 15 22 share of profit 4 7 Dividends paid 3 1 currency translation gain loss 1 6 adjustment arising from change in non-controlling interests 7 At 31 December 17 15 in 2012, the group acquired an additional 9.8% stake in Promopharm for a cash consideration of $12 million, bringing the total ownership to94.1%.
this was completed as part of a mandatory tender offer, which closed on 6 January 2012.
33. oWn sHares own shares represent 288,084 2012: 270,651 ordinary shares in the company held by sanne trust company limited, an independent trustee.
During the year, the company issued 685,540 ordinary shares and purchased 210,000 ordinary shares from the independent trustee tomeet short-term commitments in relation to employee share plans.
793,570 shares were utilised during the year.
the market value for own shares at 31 December 2013 was $7 million 2012: $3 million.
the book value of the retained own shares at 31 December 2013 is $3 million 2012: $nil.
the trustee holds these shares to meet long-term commitments in relation to employee share plans.
